This report is based on twenty-eight (26%) of 107 patients included in a protocol for prospective evaluation of elective peritoneo-venous shunting for intractable ascites in cirrhosis. These patients had no other procedures and survived more than 5 years after the operation. All patients were free of ascites except one in whom it was mild. One patient refused follow-up. Shunt patency was assessed in 23 patients.
INTRODUCTION
Intractable ascites is a serious complication of liver cirrhosis. The prognosis is dismal and the one year survival is 4-37.5% C1-4). There are two available surgical treatments. Portocaval shunt efficiently clears ascites but carries a high postoperative complication rate and a significant incidence of encephalopathy C5-9). The alternative treatment is peritoneovenous shunting (PVS), which more than ten years after the original description C10) is still not widely accepted ca, [11] [12] [13] [14] . The main criticisms of this procedure are" significant operative mortality, high shunt failure rates and poor long term results ca, [12] [13] [14] [15] . However, recent improvements in materials (16) and a better understanding of physiological changes after PVS (17) (18) (19) (20) (21) (22) (23) (LeVeen) shunt for the treatment of intractable ascites complicating chronic liver disease. All patients were referred by hepatologists following the failure of intensive medical therapy (hospitalization, salt restriction, intensive diuresis, repeated paracentesis), aggressively pursued for an average of 5.5 months. Details of this study were reported elsewhere (22) . On December 31st. 1986, 33 patients (30.8%) were alive, 7 were lost to follow-up and 67 had died (Table I) . Life table analysis is seen in Figure   1 . No data are available on PVS patency in these latter 74 patients. Five (25) . Full liver function tests were performed and the patients were reclassified according to Child's criteria as modified by Pugh et al (26) and compared to their pre PVS score. Every patient had an ultra-sound. The patency of the shunt (23 patients) and that of the superior vena cava (SVC) (14 patients) were assessed radiologically as previously described (15) Figure 2 . It is apparent that in all the 27 patients, the Pugh score improved after PVS becoming normal in 21; serum albumin improved in 18, prothrombin time in 8 and bilirubin in 2. In one patient mild ascites accounted for a score of 6. In the five others scores of six in 3 and seven in 2 were the result of low serum albumin concentration, slightly elevated serum bilirubin concentration or mild encephalopathy. (4, 6, 7) .
Of interest is the high incidence of shunt occlusion (60% of patients studied), yet these patients were free of ascites. Combined with the 26% survival, it calculates that only 12% of the 107 shunts that were placed were patent at the five-year point. The high incidence of SVC thrombosis (26%) is also significant and represents a serious complication for the patient who might be considered a candidate for liver transplantation in the future. The identification of an occluded shunt in the absence of ascites has significant implications regarding the pathogenesis of ascites. The LeVeen shunt has been used as a tool to unravel the etiological factors in the ascites associated with cirrhosis and portal hypertension 8). In general, these have been studies of the acute effects of peritoneovenous shunting although longer term follow-up studies have recognized a persistent inability of the cirrhotic patient to handle a sodium load. In this five-year follow-up study, 60% of survivors had an occluded shunt, yet were free of ascites without diuretic therapy. The implication is that the sodium-retaining lesion that these patients had preoperatively is reversible in the long term. Whether this primary lesion is peripheral arterial vasodilation and vascular unresponsiveness remains to be determined (9) . The authors could identify no difference in the preoperative status of patients with an occluded shunt and patients with a patent shunt; it is open to speculation whether those patients with a patent shunt had the same reversible lesion, and whether the shunt was "functionally patent".
The high rate of late cancers is interesting. However, the numbers are so small that it is difficult to regard peritoneovenous shunting as being a significant cancer risk, since the incidence of esophageal, laryngeal and tonsillar carcinomas are more frequent in the alcoholic population than in the general population, and hepatocellular carcinoma is more common in cirrhotics. This long-term study has confirmed that when patients do well following peritoneovenous shunting, the results are very good. The 26% actual five-year survival and the 40% patency rate in survivors combined with the well-recognized 10-25% operative mortality rate, all emphasize the high risk nature of the patient population.
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